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Summary
The biological role of interleukin 6 (IL6) molecules in human B cell tumorigenesis was studied
by using an episomal expression vector, pHEBoSVIL6, to introduce stably the human IL6 gene
into human Epstein Barr virus (EBV)-transformed B lymphoblasts. The gene was present in
the IL6-transfected cells in a high copy number and was efficiently expressed, resulting in the
secretion of consistent levels of 11,6 molecules. The constitutive expression of the IL6 gene led
to an altered pattern of growth and to a malignant phenotype, as shown by clonogenicity in
soft agar cultures and tumorigenicity in nude mice. These data suggest that the combined action
of EBV, which exerts an immortalizing function, and of the growth-promoting activity of IIr6
molecules, can give rise to fully transformed B cell tumors in immunodeficient subjects.
E
BV is a herpes virus that preferentially infects B lympho-
cytes and induces proliferation, Ig secretion, and immor-
talization, giving rise to long-term lymphoblastoid B cell lines
(LCL)t (1). EBV infection appears to play a pathogenetic role
in the development of endemic Burkitt lymphoma (eBL) and
in the recently identifiedAIDS-associated Burkitt lymphoma
(AIDS-BL) (2-4). The nontumorigenic capabilities of LCL
suggest that the neoplastic EBVinfected clones present in eBL
and AIDS-BL may have acquired a malignant phenotype
through additional pathogenetic events, possibly mediated
by a deregulated expression of oncogenes (5, 6). As shown
for a variety of neoplastic cell types, the continuous prolifer-
ation of EBVinfected B cells appears to depend on autocrine
secretion of cytokines, including IL A and B cell growth
factor-like molecules (7-10). IL6 is a glycoprotein secreted
by a variety ofcell types, e.g., monocytes, fibroblasts, certain
T cell lines, and myeloma cells (11). Its biological action in-
cludes the growth stimulation of plasmacytomas and some
EBV lymphoblastoid B cell lines (12, 13). To investigate
whether EBV infection, which exerts a typical immortalizing
function, cooperates with the B cell growth-promoting ac-
tivity of 11,6 in inducing B cell tumorigenesis, we transfected
ROHA-9 MC3 cells, an EBV B cell line (8, 9), with an ex-
pression vector that allows a constitutive expression of the
1 Abbreviations used in this paper: BL, Burkitt lymphoma; eBL, endemic
BL; LCL, lymphoblastoid cell lines.
humanIL6 cDNA. Our results indicate that hyper-expression
of an exogenous 11,6 gene in EBVimmortalized B cells results
in a dramatic decrease in the requirement for exogenous growth
factors with the development ofa fullytumorigenic phenotype.
Materials and Methods
Animals andReagents.
￿
4-wk-old Swiss female mice were pur-
chased from Charles River Breeding Laboratories (Italy). LPS Esch-
erichia coli 055:B55 was obtained from Difco Laboratories (Detroit,
MI); Plasmid pHEBoSV and pUC9 (3221 were obtained from R.
Dalla Favera and P. B. Segal, respectively, hygromycin B was pur-
chased from Boehringer Biochemica (Italy); F(ab)2 fragments of
goat antibodies to human or mouse Igs and Leu 16 mAb (anti-
CD20) were obtained from Kallested (Austin, TX) and Becton-
Dickinson (Italy), respectively. B6 mAb (anti CD23), W6/32mAb
(anti-human MHC class I), and OKDR (anti-human MHC class
II) were purchased from Coulter Immunology (Hialeah, Florida),
Seralab (Sussex, England), and Ortho Diagnostics (Raritan, NJ),
respectively. rIL6, specific activity 1 x 10' U/mg, was kindly
provided by T Kishimoto; goat polyclonal antibody to IL -6 (specific
inhibitory activity 102 U/P.l) was the gift of J. Van Damme.
Cells and Culture Conditions.
￿
The establishment and character-
ization of the EBV' ROHA-9 and ROHA-9MC3 cells have been
previously reported (8, 9). Cells were cultured in DME sup-
plemented with 10% vol/vol inactivated FCS (Flow Laboratory)
or in HB101 medium (HangBiologics,Berkeley, CA). Media were
additioned with 3 mM glutamine and 10 mM Hepes buffer, pH
7.2 (Gibco Laboratories, Grand Island, NY). Where indicated, cells
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goat antibodies to human or mouse Igsand forCD20, CD23,MHC
class I and class II expression by flow cytometry (Ortho Spectrum
Cytofluorography, Ortho Diagnostics, Italy) . Human monocytes
were isolated from PBMC by discontinuous Percoll gradients as
described (14) with minor modifications .
Plasmid Construction and Transfection.
￿
To generate thepHEBoSV
IL6 plasmid, the human 11,6cDNA was isolated from pUC9 (3221
plasmid (15) by HindIII-SalI digestion and ligated to the HindIII-
Sall sites of pHEBoSV plasmid (5) by standard techniques (16) .
Cells were transfected by electroporation (17) . Cells were washed
and resuspended in 0.8 ml of Cal* and Mgt'-free PBS (D-PBS)
at a concentration of 1.5 x 10'/ml in the presence of 10 Ag of
intact pHEBoSV or pHEBoSVIL6 plasmids. Cells were subjected
to a single electrical pulse (0.2 kV, 960 p,FD, 15 ms) using a Bio
Rad apparatus, recovered, and cultured for 48 h in DME sup-
plemented with 10% FCS before selection in 300 Wg/ml of
hygromycinB . Stable bulk cultures were obtained after 3 wk and
subjected to limiting dilution cultures (0.2 cells/well) to obtain
MC3-IL6 subclones . Cells were routinely cultured in hygromycin
B-supplemented medium .
DNA andRNA Analysis .
￿
Low molecular weight DNA was
isolated according to Hirt (18), electrophoresed in 0.6% agarose
gel, blottedon Gene Screen Plus filters (Du Pont, Italy), and ana-
lyzed by Southern blot using an 11,6 cDNA probe 32P-labeled to
a specific activity of 0.8-1.0 x 109 cpm/lzg by random hexamer
method (19) . Hybridization wasperformed at 65°Cin 1M NaCl,
10%dextran sulfate, 1% SDS, 100,ug/ml denaturedsalmon sperm
DNA. Washing was performed at 65°C as suggested by the
manufacturer. TotalRNAwas extractedby the guanidine-isothio-
cyanate method, electrophoresed in 1% agarose/2.2M formalde-
hyde gels, and then transferred to nylon filters (GeneScreen Plus)
by Northern blot . Hybridization and washing were performed as
described above . The amounts ofRNA were calculated by absor-
bance at 260 nm and by equalization on agarose gel electropho-
resis . After hybridization, the amounts of transferredRNA were
checked by staining the filters with 0.04% methylene blue as de-
scribed by Maniatis et al . (16) .
Cell Growth Assay.
￿
To assay the secretion ofIL-6 moleculesby
the transfected cells, supernatant fluids from control and IL6-
transfected cells were collected during the logarithmic growth of
the cells, dialyzed extensively against DME, filtered (0.2 ,um), and
analyzed for their capacity to sustain the growth of the IL-6-
dependent 7TD1 hybridoma cells . The assaywasperformed essen-
tially as described (20), except that cold thymidine was omitted
from the assaymedium .Growth in soft agar was assayed by plating
10 3 , 5 x 103, and 1 x 104 cells in 3 ml of medium supplemented
with 20% FCS and 0.3% agar in 30-mm culture plates . Cultures
were scored for colonies 14 d following seeding . Aggregates of at
least 50 cells were considered colonies.
Tumorigenicity in ImmunodeficientMice .
￿
Tumorigenicity was as-
sayed essentially as described (21) . Briefly, 4-wk-old Swiss female
nude mice (Charles River Breeding Laboratories) were injected sub-
cutaneously with 5 x 106 cells in0.2 ml of PBS. Tumor diagnosis
was confirmed by standard histological examination ; representa-
tive tumor samples were analyzed forB cell surface markers by
flow cytometry.
Results and Discussion
To obtain a constitutive expression of human IL6 cDNA
in EBVinfected lymphoblasts, an appropriate plasmid was
developed using the vector pHEBoSV, which carries the
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hygromycin Bresistance gene together with theEBV origin
ofreplication (oriP) (5, 22) . TheIL6cDNA coding sequences
were excised from the pUC9 0221 plasmid (15) and inserted
downstream to the SV40 promoter element of pHEBoSV
plasmid (Fig. 1A) . The pHEBoSVIL6 and pHEBoSV con-
trol vectorswere transfectedby electroporation into ROHA-
9MC3 EBVB cell line (hereafter referred to as MO) (9) .
Following selection of the transfected cells in medium sup-
Figure 1.
￿
Schematic representation of the pHEBoSVIL6 vector and
evidence of its extrachromosomal copies in transfected cells. (A) Rele-
vant regions of the pHEBoSVIIL6 plasmid are indicated by boxes
marked as follows: SV40, SV40 enhancer/promoter region; 11,6
cDNA, full length human IL6 cDNA; EBVorip, EBV origin of repli-
cation; Hyg`, hygromycin 13-resistance gene flanked by the thymidine
kinase promoter and polyadenylation regions ; Amp', ampicillin-
resistance gene. Restriction sites: H, HindIII ; S, Sall; E, EcoRl. (B)
Southern blot analysis of transfected plasmids. Low molecular weight
DNA was extracted from pHEBoSVIL6 or pHEBoSVtransfected
cells, transferred to nylon membrane and probed with a 32p-labeled
IL6 cDNA. (Lanes a-b) HindIII digested and undigested pHEBoSV
IL6 plasmid (1 ng); (lanes cA undigested and HindIII-digested
plasmid DNA of MC3-IL6-9 cells ; (lanes e1) undigested and
HindIII-digested plasmid DNA of MC3-IL6-11 cells ; (lanes g-h) un-
digested and HindIII-digested plasmid DNA of MC3-pHEBoSV con-
trol cells . In the undigested samples the multiple bands correspond to
the different circular forms of the transfected plasmid . Similar results
were obtained in the case of control cells and other 11,6-transfected
bulk cultures and clones (not shown) .plemented with hygromycin B (300 wg/ml), bulk cultures
of 11,6-transfectedMC3 cells (MC3-IL6) orMC3-pHEBoSV
were obtained. The MC3-IL6 cells were then subjected to
limiting dilution cultures (0.2 cells/well) to obtain cell clones .
The MC3-IL6-9, MC3-IL6-11 bulk cultures and the MC3-
IL6-2C4 and MC3-IL6-2A2 clones were randomly selected
for the present study; MC3-pHEBoSV bulk cultures served
as controls .
The presence of intact vectors in transfected cells was
confirmed by Southern analysis of low molecular weight
DNA . As shown in Fig. 1 B, the vectors were present as
extrachromosomal plasmids with a copy number of N5-10
per cell . No integrated copies of the plasmids were revealed
by Southern analysis of genomic DNA (not shown) . The
expression of the transfected IL6 cDNA was examined by
Northern blots of total RNA from the MC3-IL6 cells by
using an 11,6-specific probe. As shown in Fig . 2 A, all the
transfected MC3-IL6 clones expressed high amounts of 11,6
mRNAs, whereas the MC3-pHEBoSV control cells showed
low levels of specific IL6mRNA transcripts. Moreover, the
MC3-1L6 cells secreted high levels of 11,6 activity, as assayed
by the IL-6-dependent 7TD1 hybridoma cell line (20) (see
Fig. 2 B) . On a per cell basis, the transcription and secretion
ofIL6 was higher inMC3-9, MC3-11, MC3-2C4, and MC3-
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2A2 cells than in LPS-activated monocytes, while the MC3-
pHEBoSV control cells secreted very low amounts of 11,6 .
To test whether the IL6 expression may lead to an altered
requirement for serum growth factors, theMC3-IL6 cells were
cultured in serum-free medium at different cell concentra-
tions as previously reported (9) . As shown in Fig . 3 A, the
MC3-IL6-9 cells were able to proliferate even when cultured
at very low cell concentrations. Under the same culture con-
ditions, the MC3-pHEBoSV control cells failed to elicit a
significant proliferation unless the cultures were supplemented
with a conditioned medium from MC3-IL6-9 cells . Similar
results were obtained using the other IL6-transfected cells
(not shown) . This indicated that the requirement for exoge-
nous growth factors was decreased in the IL6-expressing cells,
suggesting that the IL-6 molecules could function as auto-
crine factors for the MC3-IL6 cells . In fact, IL-6 molecules
were secreted by the cells and present in culture medium .
This possibility was further tested in the experiments illus-
trated in Fig. 3 (bottompane . Control and IL6-transfected
cells were cultured at 5 x 104/ml cell concentration in HB-
101 serum-defined medium (9) and supplemented with op-
timal concentrations of IL-6 . While the control cells retained
the capacity to proliferate in response to 11,6, as previously
reported for other EBV B cell lines (13), the 11,6-transfected
Figure 2 .
￿
Northern blot analysis of
IL-6 transcripts and IL-6 secretion in
transfected MC3 cells. (A) Total cellular
RNA was extracted from MC3 cells
transfected with the pHEBoSVIL6 or
pHEBoSV control vector and from
human adherent monocytes stimulated
with LPS (1 Aglml) for 6 h . RNA
samples were separated on 1% denaturing
agarose gel, transferred to nylon mem-
branes, and hybridized as detailed in
Materials and Methods. (Lane a) RNA
from LPS-activated monocytes ; (lanes b
through e) RNA from MC3-IL6-9, 11,
2C4, and 2A2 cells ; (lane f) RNA from
MC3-pHEBoSV control cells. (B) The
secretion of IL-6 molecules by the trans-
fected cells was assayed by using the IL-
6-dependent 7TD1 hybridoma cells (20) .
Data express the IL-6 activity secreted by
5 x 10 5 MC3 cells and human mono-
cytes . (O), MC3-pHEBoSV; ('), MC3-
IL6-2A2 ; (E), MC3-IL6-9 ; (" ), MC3-
IL6-11 ; (A), MC3-IL6-2C4 ; (A), LPS-
stimulated human monocytes.Table 1 .
￿
In Vitro Cloning Efficiency and In Vivo Tumorigenicity ofII-6-transfected MC3 Cells
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Figure 3 .
￿
Constitutive expression of
IL-6 gene alters the growth of the MC3-
IL6 cells . (A) MC3-pHEBoSV (O) and
MC3-IL6-9 (/) cells were cultured for
48 h at the indicated cell concentrations
in HB-101 serum-defined medium as pre-
viously described (9) . In parallel cultures
(" ), control MC3-pHEBoSV cells were
cultured in presence of dialyzed condi-
tioned medium obtained from MC3-IL6-9
cells cultured in HB-101 medium and
tested at 25% final dilution. (B) The
modulation of the growth response to ex-
ogenous IL-6 molecules was performed es-
sentially as described (9) . Briefly, cells
were cultured in HB-101 medium at 5 x
103/well in 0 .2 ml cultures for 48 h in
presence of (a) control goat serum ; (b)
human rIL6 (5 ng/ml, specific activity
1 x 107 U/mg), or (c) IL-6 and a goat
antiserum to IL-6 (1:200 final dilution)
(28) . Cultures were pulsed for the last
5 h with 0 .5 p.Ci of [ 3H]thymidine be-
fore harvesting and analysis. Data are ex
pressed as absolute cpm per 10' cells .
' Growth in soft agar was assayed as detailed in Materials and Methods . Data are expressed as number of colonies per 10 -4 cells and are the
arithmetic mean of triplicate cultures . SEM were <10% of the mean values .
t Tumorigenicity was assayed by a single subcutaneous injection of 5 x 10 6 cells in 0.2 ml of PBS . Typically, tumors >5 mm in diameter
developed after 2-3 wk of latency at the challenge site and in the regional lymph nodes . Data are the numbers of tumors recorded through
6 wk of observation .
S Positive control .
Cell line
Cloning
efficiency'
Tumorigenicity in vivot
Number of mice with tumors/
number of inoculated mice
Average of tumors
per mouse
MC3-pHEBoSV 0 0/6 0
MC3-IL6-9 120 4/4 3.5
MC3-11,6-11 80 4/4 2.5
MC3-IL6-2C4 78 3/4 3.0
MC3-IL6-2A2 148 5/5 4.0
BL (Daudi)S 166 5/5 4.0cells showed a baseline increase in [3H]thymidine uptake and
were unresponsive to the exogenous 11,6 molecules . This may
depend on a saturation of 1166 surface receptors by the con-
stitutively secreted I1r6 molecules . In parallel cultures, the
addition of a goat polyclonal antibody to IL6 molecules
resulted in a partial decrease in the constitutive proliferation
of the MC3-IL6 cells, while the IL6-induced proliferation
ofMC3-pHEBoSV cellswas significantly inhibited . This again
suggests a high level of occupancy of surface receptors by
the secreted IL6 molecules. Alternatively, the expression of
the IL6 gene in the transfected clones may have resulted in
the constitutive activation of different pathways for B cell
proliferation, e. g., receptor transduced or intracellular signals
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ofactivation. These latter mechanisms ofproliferation would
not be affected by antibodies to IL6 . Indeed, the gene coding
for the IL6 receptor was transcriptionally upregulated in
MC3-IL6 cells (Scala, G ., work in progress) .
The altered growth properties of theMC3-IL6 cells were
also studied by examining their ability to form colonies in
soft-agar cultures, a propertycommon tomany naturally oc-
curring B cell neoplasias (23) . As shown in Table 1, the
MC3-IL6 cells exhibited a significant increase in their clo-
nogenic capabilities, while the control MC3-pHEBoSV cells
did not form colonies under the same culture conditions, there-
fore behaving as a common EBVinfected B cell line. In par-
allel experiments, exogeneous 11,6 (up to 103 U/ml) only
Figure 4 .
￿
(A, B) Pathological
findings in mice injected with MC3-
IL6 cells. Cytological picture of
tumor cells obtained after 3-4 wk
from the injection site (A, Papanico-
laou, x430 ; B, Papanicolaou, x1,060) .slightly increased the clonogenic properties of the MC3-
pHEBoSV control cells and was uneffective on the growth
of the IIr6-transfected MC3 and Daudi cells (not shown) .
The clonogenic potential of transformed cells is often as-
sociated with a tumorigenic phenotype (23, 24) . To test
whether the MC3-11,6 cells could have acquired a malig-
nant phenotype, we subcutaneously injected various B cell
populations into nude mice. As shown in Table 1, theMC3-
IIr6 B cells gave rise to tumors in nude mice, whereas the
control MC3-pHEBoSV cells were not tumorigenic . The
tumors appeared subcutaneously 10-15 d after the injections,
and showed a histological picture of homogeneous infiltrating
B cell populations . These cells were characterized by eccen-
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tric nucleolated nuclei and large cytoplasms with peripheral
condensation (Fig. 4, A, B) . These immunoblastic-like cells
were shown to infiltrate periglandular lymphonodes (Fig. 5,
A, B) . In the tumor-bearing mice, however, the secretion
of IIr6 by MC3-IIs6 cells could have induced a polyclonal
proliferation of mouse B cells that could account for the
tumoral masses . To test this possibility, tumor cells from mice
injected with MC3-IL6 cells were examined for the expres-
sion of CD20, CD23, MHC class I and class II molecules,
and for mouse andhuman surface Igs (p., S, -y, « specificities) .
In these experiments, both the original and tumor MC3-IIx
6 cells showed a similar flow cytometry profile (data not
shown) . Moreover, analysis of the low molecular weightDNA
Figure 5 .
￿
(A, B) Hematcncylin and
eosin (A, x270; B, x1,060) of a peri-
glandular lymph node showing a follicle
infiltrated by immunoblastic cells (arrow) .oftumor cells showed the presence ofpHEBoSVIL6 plasmids
(not shown).
The immortalizing function of EBV infection is not usu-
ally associated with tumorigenic capabilities that are often
present in naturally occurring EBV+ B lymphomas, includ-
ing eBL and the recently identified AIDS-BL (2-4). This in-
dicated that other pathogenicevents, in addition to EBV in-
fection, may be involved in B cell tumorigenesis. Indeed, the
nontumorigenic properties of in vitro infected EBV B cells
suggest that additional pathogenic events have occurred in
spontaneous EBVrelated B lymphomas.
The growth of neoplastic lymphoid cells of both T and
B phenotypes is often dependent upon interleukin-like growth
factors that share most of the biochemical and biological prop-
erties of the factors secreted and used by normal lymphoid
cells (9, 25). Among these growth factors, 11,6 has been re-
cently identified as a growth and differentiation factor for
both normal and transformed B cells (11). In this study, we
attempted to drive an EBV B cell line, MC3, to a malignant
phenotype by inserting a constitutively expressed IL6 gene.
Present in an episomal replicating plasmid, the gene was stably
present in transfected cellswith a high copy number and ex-
pressed high levels ofthe exogenous IL-6 gene. The resulting
MC3-1176 cells showed a donogenic capacity and were tumori-
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